Bayer IR Newsfeed: EventsBayer IR Newsfeed: Investor News31.08.08: Secondary prevention in acute coronary syndrome (ACS):- August 31, 2008 Rivaroxaban Phase II Data in ACS to be Presented at AHA Congress in November 2008First data presentation from large dose-finding trial involving about 3,500 patients Acceleration of clinical development in acute coronary syndrome plannedmehr ...http://www.investor.bayer.de/no_cache/en/news/investor-news/investor-news/showNewsItem/986 27.08.08: New Bayer CropScience active ingredient approved in Romania:- August 27, 2008 Thiencarbazone-methyl registered in first market Annual sales potential of more than EUR 100 million for new corn herbicidemehr ...http://www.investor.bayer.de/no_cache/en/news/investor-news/investor-news/showNewsItem/984 21.08.08: Bayer and Onyx continue clinical investigation of sorafenib:- August 21, 2008 New Trial to Evaluate Nexavar as Adjuvant Therapy in Liver CancerEnrollment initiated in international phase III studymehr ...http://www.investor.bayer.de/no_cache/en/news/investor-news/investor-news/showNewsItem/982 21.08.08: Further expansion of activities in China:- August 21, 2008 Bayer MaterialScience starts construction of a world-scale TDI plant in ShanghaiAnnual capacity of 250,000 metric tons approved Capacity can be increased to 300,000 metric tons per year Start-up planned for 2010mehr ...http://www.investor.bayer.de/no_cache/en/news/investor-news/investor-news/showNewsItem/980 19.08.08: Bayer HealthCare and Regeneron Announce VEGF Trap-Eye Achieved Durable Improvement in Vision over 52 Weeks in a Phase 2 Study in Patients wi- August 19, 2008 Bayer HealthCare and Regeneron Announce VEGF Trap-Eye Achieved Durable Improvement in Vision over 52 Weeks in a Phase 2 Study in Patients with Age-related Macular DegenerationStudy patients, on average, received only two additional doses following a 12-week fixed dosing periodmehr ...http://www.investor.bayer.de/no_cache/en/news/investor-news/investor-news/showNewsItem/978 07.08.08: Bayer Schering Pharma strengthens its oncology R&D portfolio- August 7, 2008 Bayer acquires Preclinical Anti-cancer Program from NycomedCompany assuming full development and commercialization rightsmehr ...http://www.investor.bayer.de/no_cache/en/news/investor-news/investor-news/showNewsItem/975 05.08.08: Bayer MaterialScience raises price for MDI- August 5, 2008 Bayer MaterialScience raises price for MDImehr ...http://www.investor.bayer.de/no_cache/en/news/investor-news/investor-news/showNewsItem/973 |